Literature DB >> 25562596

Renal cell carcinoma with t(6:11) (p21;q12). A case report highlighting distinctive immunohistologic features of this rare tumor.

Sarabjeet Kaur Arneja1, Neeraj Gujar2.   

Abstract

INTRODUCTION: Renal cell carcinoma (RCC) with t(6:11) (p21;q12) are extremely rare, fewer than 30 cases have been reported in literature. These tumors are characterized by specific chromosomal translocation involving TFEB, as against the more commonly known TFE3 (Xp11.2) translocation associated RCCs. The distinctive immnohistologic features are helpful in enabling a diagnosis of this rare tumor, otherwise diagnosed by fluorescence in situ hybridization assay, specific for detecting TFEB gene rearrangement. PRESENTATION OF CASE: Herein, we report a case of this rare tumor in a 11 years old boy, with the objective of highlighting distinctive light microscopic and immuno-phenotypic features of this rare sub-type of translocation associated renal cell carcinoma, otherwise diagnosed by fluorescence in situ hybridization technique. Morphologically tumor showed distinctive biphasic population of cells, large epitheloid cells with voluminous eosinophillic cytoplasm and smaller cells with much lesser amount of cytoplasm and small rounded nuclei. The smaller cells at places clustered around hyaline pink material forming "pseudorosettes". population. Immunohistochemically both types of tumor cells showed negativity for pan CK (cytokeratin), EMA (epitheleal membrane antigen) and TFE3 (transcription factor E3). HMB 45 (human melanoma black 45) and Melan- A /MART 1 (melanoma antigen recognized by T cells) were moderate to strongly expressed. DISCUSSION: On review of literature, most RCCs with t(6;11) translocation have been reported to be negative for pan cytokeratins and EMA. Published literature also shows that the most distinctive immunohistochemical feature of t(6;11) translocation RCC is nuclear staining for TFEB protein. Immunostains for TFE3 have always been negative in the reported cases. It is noteworthy that immunoreactivity for melanocytic markers HMB45 and Melan A and immunonegativity for epithelial markers pan CK and EMA may lead to misdiagnosis of angiomyolipoma to the unwary.
CONCLUSION: Knowledge of distinctive morphological and immuno-histochemical features of this tumor can help in establishing a diagnosis of this rare subset of translocation associated RCC on routine hematoxylin and eosin (H and E) staining and immunophenotyping.
Copyright © 2014 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Immuno-histology; RCC; Renal cell carcinoma; TFE3; TFEB; q12); renal cell carcinoma; t(6:11) (p21;; translocation factor E3; translocation factor EB

Year:  2014        PMID: 25562596      PMCID: PMC4336393          DOI: 10.1016/j.ijscr.2014.12.026

Source DB:  PubMed          Journal:  Int J Surg Case Rep        ISSN: 2210-2612


Introduction

Renal cell carcinoma (RCC) with t(6:11) (p21;q12) are extremely rare, fewer than 30 cases have been reported in literature [1-3]. These tumors are characterized by a specific chromosomal translocation involving the transcription factor EB (TFEB) [4]. This distinctive tumor was first described by Argani et al. [4]. Increasing evidence has shown that these tumors possess unique morphologic and immunohistochemical features. The identification of overexpression of TFEB protein by immunohistochemistry or detecting a t(6:11) (p21;q12) translocation by fluorescence in situ hybridization is necessary for accurate diagnosis [5]. We hereby present a case report of this rare tumor in a 11 year old boy, with the objective of highlighting its distinctive immuno-histologic features.

Case report

Patient, a 11 years old boy, presented at our institute with complaints of lump in the right hypochondrium noticed since last 10 days. He also complained of fever since last 10 days. No history of trauma or any other significant past history was reported. An ultrasound study revealed a large heterogeneous appearing mass lesion arising from upper and mid pole of the right kidney with increased vascularity. CT scan showed a large heterogenously enhancing mass lesion arising from the upper pole of right kidney with arterial enhancement and washout on delayed phases, suggestive of neoplastic etiology. A possibilty of Renal Cell Carcinoma or Wilm’s Tumor was suggested. A right radical nephrectomy was performed and sent for histopathological examination. Bisected kidney showed a large well-delineated, nodular, tan- brown colored, soft to firm tumor measuring 13.7 × 11.0 × 8.0 cm, nearly completely replacing the normal renal parenchyma (Fig 1A). No necrosis was identified. Morphology revealed a biphasic population of cells (Fig 1B and C), large epitheloid cells with voluminous eosinophilic cytoplasm and smaller cells with much lesser amount of cytoplasm and small rounded nuclei. The smaller cells at places clustered around hyaline pink material forming “pseudorosettes”(Fig 1D). Dark brown pigmentation was observed in small cell population. Immunohistochemically (Fig 2A–E) both types of tumor cells showed negativity for pan CK (cytokeratin), EMA (epitheleal membrane antigen) and TFE3 (transcription factor E3). HMB 45 (human melanoma black 45) and Melan A/MART 1 (melanoma antigen recognized by T cells) were moderate to strongly expressed. Subsequently, fluorescence in situ hybridization studies done at an outside referral institute showed t(6:11) (p21;q12) renal cell carcinoma.
Fig. 1

(A) Gross findings on Nephrectomy specimen: large well-delineated, nodular, tan- brown colored tumor nearly completely replacing the normal renal parenchyma. (B) H and E10× (C) H and E 20×: biphasic population of cells, large epitheloid cells with voluminous eosinophillic cytoplasm and smaller cells with much lesser amount of cytoplasm and small rounded nuclei. (D) The smaller cells at places clustered around hyaline pink material forming “pseudorosettes”.

Fig. 2

Immunohistochemistry: (A–C) pan CK, EMA and TFE3, respectively. Immunonegative for pan CK, EMA and TFE3. Note nuclear nonreactivty for TFE3. (D) HMB45 and (E) Melan A. Immunopositivity for HMB45 and Melan A.

Materials and method

Tissue was fixed in 10% neutral buffered formalin and embedded in paraffin. Immunohistochemical analysis was done using following antibodies: pan CK (AE1 and AE3,Biogenex), EMA (E29, Biogenex), TFE3 (MRQ-37, Cell Marque, 1:100), HMB45 (HMB45, Biogenex), and Melan A (Clone A103, Dako). Immunoreaction was performed using the Horse Radish Peroxidase- conjugated streptavidin (Biogenex Polymer HRP kit). Diaminobenzidine (DAB) was used as chromogen.

Discussion

t(6:11) (p21;q12) associated RCCs are rare subsets of the distinctive entity of translocation associated RCCs as described in 2004 WHO classification of renal tumors [6]. These translocations most frequently involve the TFE3 gene on locus Xp11.2 and less frequently involve the TFEB gene on locus 6p21 [7]. Less than 30 cases of t(6:11) (p21;q12) associated RCCs have been reported in literature [1-3]. Recently Rao et al. reported additional 7 cases [8]. The translocation of t(6;11)(p21;q12 or q13) causes fusion of Alpha gene on 11q12 or q13 with the TFEB gene on 6p21, this results in overexpression of native TFEB protein. Review of the published data indicates that RCC with t(6;11) translocation is seen predominantly in children and young adults, minority of patients being older adults [9]. The patient in our case is 11 years old. Microscopically as in our case biphasic pattern of tumor, constituted by large epitheloid cells with voluminous pink cytoplasm and smaller cells centered around hyaline material, so called ‘pseudorosette’ pattern was the most common pattern. Published literature also shows that the most distinctive immunohistochemical feature of t(6;11) translocation RCC is nuclear staining for TFEB protein [10-12]. Argani et al. [2] detected strong nuclear TFEB labeling in all seven RCCs with t(6;11) translocation studied, in contrast to 1089 other unrelated neoplasms and normal tissues that showed negativity for nuclear labeling of this protein. Noteworthy fact is that melanocytic markers HMB45 and Melan-A are commonly positive in these tumors [4,5]. Moderate to strong expression of HMB45, and Melan-A was seen in our patient case as well. TFEB was however not performed in our case. Most RCCs with t(6;11) translocation are negative for pan cytokeratins and EMA. Only four patient cases have been positive for pan CK [1,3,12] and two have been positive for EMA [5]. Immunostains for TFE3 have always been negative in the reported cases [1,2,4,5,9-11] It is noteworthy that immunoreactivity for melanocytic markers HMB45 and Melan A and immunonegativity for epithelial markers pan CK and EMA may lead to misdiagnosis of Angiomyolipoma to the unwary [9]. This tumor is so far a patholologically and molecularly defined entity. Due to its rarity the clinical behavior of these tumors remains uncertain. One such case study of 7 cases where follow up was available on 6 cases, has shown no evidence of recurrent disease or disease progression after initial surgical resection, indicating thereby that this may represent an indolent tumor [8]. Our case also has been followed up for one year and is free of recurrent disease. However the available data represent a small sample and a short term follow up and may not represent the true nature of these tumors. In conclusion, knowledge of distinctive morphological and immunohistochemical features of this tumor can help in establishing a diagnosis of this rare subset of translocation associated RCC on routine hematoxylin and eosin (H and E) staining and immunophenotyping.

Conflicts of interest

None whatsoever.

Funding

Non sponsored.

Ethical approval

Approval taken. Referrence Number - P52.

Author contribution

Dr Sarabjeet Kaur Ist Author-Study concept, data analysis or interpretation, writing the paper.Neeraj Gujar-2nd Author, Data collection and writing the paper.

Consent

Patients guardian’s consent taken.

Guarantor

Dr Geeta Koppikar, Medical Director Breach Candy Hospital Trust, Mumbai, Maharashtra 26, India.
  11 in total

1.  A distinctive pediatric renal neoplasm characterized by epithelioid morphology, basement membrane production, focal HMB45 immunoreactivity, and t(6;11)(p21.1;q12) chromosome translocation.

Authors:  P Argani; A Hawkins; C A Griffin; J D Goldstein; M Haas; J B Beckwith; C B Mankinen; E J Perlman
Journal:  Am J Pathol       Date:  2001-06       Impact factor: 4.307

2.  Renal cell carcinoma with t(6;11) translocation: a patient case with a novel Alpha-TFEB fusion point.

Authors:  He-Qin Zhan; Chao-Fu Wang; Xiong-Zeng Zhu; Xiao-Li Xu
Journal:  J Clin Oncol       Date:  2010-09-07       Impact factor: 44.544

3.  Translocation carcinomas of the kidney after chemotherapy in childhood.

Authors:  Pedram Argani; Marick Laé; Edgar T Ballard; Mahul Amin; Carlos Manivel; Brian Hutchinson; Victor E Reuter; Marc Ladanyi
Journal:  J Clin Oncol       Date:  2006-04-01       Impact factor: 44.544

4.  Renal cell carcinomas with t(6;11)(p21;q12): A clinicopathologic study emphasizing unusual morphology, novel alpha-TFEB gene fusion point, immunobiomarkers, and ultrastructural features, as well as detection of the gene fusion by fluorescence in situ hybridization.

Authors:  Qiu Rao; Biao Liu; Liang Cheng; Yun Zhu; Qun-Li Shi; Bo Wu; Shao-Jun Jiang; Yan Wang; Xuan Wang; Bo Yu; Ru-Song Zhang; Heng-Hui Ma; Zhen-Feng Lu; Pin Tu; Jian-Dong Wang; Xiao-Jun Zhou
Journal:  Am J Surg Pathol       Date:  2012-09       Impact factor: 6.394

Review 5.  2004 WHO classification of the renal tumors of the adults.

Authors:  Antonio Lopez-Beltran; Marina Scarpelli; Rodolfo Montironi; Ziya Kirkali
Journal:  Eur Urol       Date:  2006-01-17       Impact factor: 20.096

6.  Renal carcinomas with the t(6;11)(p21;q12): clinicopathologic features and demonstration of the specific alpha-TFEB gene fusion by immunohistochemistry, RT-PCR, and DNA PCR.

Authors:  Pedram Argani; Marick Laé; Brian Hutchinson; Victor E Reuter; Margaret H Collins; John Perentesis; John E Tomaszewski; John S J Brooks; Geza Acs; Julia A Bridge; Sara O Vargas; Ian J Davis; David E Fisher; Marc Ladanyi
Journal:  Am J Surg Pathol       Date:  2005-02       Impact factor: 6.394

7.  Upregulation of the transcription factor TFEB in t(6;11)(p21;q13)-positive renal cell carcinomas due to promoter substitution.

Authors:  Roland P Kuiper; Marga Schepens; José Thijssen; Martien van Asseldonk; Eva van den Berg; Julia Bridge; Ed Schuuring; Eric F P M Schoenmakers; Ad Geurts van Kessel
Journal:  Hum Mol Genet       Date:  2003-07-15       Impact factor: 6.150

8.  Renal translocation carcinomas: clinicopathologic, immunohistochemical, and gene expression profiling analysis of 31 cases with a review of the literature.

Authors:  Philippe Camparo; Viorel Vasiliu; Vincent Molinie; Jerome Couturier; Karl J Dykema; David Petillo; Kyle A Furge; Eva M Comperat; Marick Lae; Raymonde Bouvier; Liliane Boccon-Gibod; Yves Denoux; Sophie Ferlicot; Eric Forest; Gaelle Fromont; Marie C Hintzy; Myriam Laghouati; Mathilde Sibony; Marie L Tucker; Nina Weber; Bin T Teh; Annick Vieillefond
Journal:  Am J Surg Pathol       Date:  2008-05       Impact factor: 6.394

9.  Translocation renal cell carcinoma: lack of negative impact due to lymph node spread.

Authors:  James I Geller; Pedram Argani; Adebowale Adeniran; Edith Hampton; Angelo De Marzo; Jessica Hicks; Margaret H Collins
Journal:  Cancer       Date:  2008-04-01       Impact factor: 6.860

10.  Renal translocation carcinoma with expression of TFEB: presentation of a case with distinctive histological and immunohistochemical features.

Authors:  Dimas Suárez-Vilela; Francisco Izquierdo-García; José Ramón Méndez-Álvarez; Erasmo Miguélez-García; Francisco Domínguez-Iglesias
Journal:  Int J Surg Pathol       Date:  2009-08-16       Impact factor: 1.271

View more
  2 in total

Review 1.  A Review of Translocation T(6;11) Renal Cell Carcinoma Tumors in the Adult Patient.

Authors:  Paulette Cutruzzula; David Cahn; Dana Kivlin; Carmen Tong; Daniel Edwards; Melanie Amster
Journal:  Curr Urol       Date:  2017-05-30

2.  t(6;11) renal cell carcinoma: a study of seven cases including two with aggressive behavior, and utility of CD68 (PG-M1) in the differential diagnosis with pure epithelioid PEComa/epithelioid angiomyolipoma.

Authors:  Anna Caliò; Matteo Brunelli; Diego Segala; Serena Pedron; Regina Tardanico; Andrea Remo; Stefano Gobbo; Emanuela Meneghelli; Claudio Doglioni; Ondrej Hes; Claudia Zampini; Pedram Argani; Guido Martignoni
Journal:  Mod Pathol       Date:  2017-10-20       Impact factor: 7.842

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.